Viewing Study NCT06363734

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:19 AM
Ignite Modification Date: 2026-05-16 @ 9:19 AM
Study NCT ID: NCT06363734
Status: RECRUITING
Last Update Posted: 2024-04-16
First Post: 2024-04-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
None EGFR Activating Mutation View
None Cell Cycle Deregulation View
None EGFR-TKI Resistant Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC View
None EGFR activating mutations View
None Third-generation EGFR-TKI View
None Cell cycle signaling pathway aberrations View
None CDK4/6 inhibitors View